FDA
-
-
-
-
-
-
-
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Cidara to present Phase 2 data on influenza drug CD388 at ID Week
-
-
-
-
-
-
-
Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic
-
-
-
-
-
-
-
Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
-
-
-
-
-
-
-
Cidara Therapeutics (CDTX) PT Raised to $66 at Citizens JMP
-
-
-
-
-
-
-
Cidara Therapeutics (CDTX) Announces Proposed $250M Share Offering
-
-
-
-
-
-
-
Cidara Therapeutics (CDTX) Appoints Nicole Davarpanah as Chief Medical Officer
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

